Acura Pharmaceuticals Inc (ACUR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Acura Pharmaceuticals Inc (ACUR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10003
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Acura Pharmaceuticals Inc (Acura) is a specialty pharmaceutical company that researches, develops, and commercializes tamper-resistant products to prevent the abuse and misuse of medication. The company’s proprietary technologies, Aversion, Limitx and Impede, are used to prevent product tampering associated with opioid abuse. Its Impede technology helps minimize the extraction and conversion of pseudoephedrine into methamphetamine. Limitx reduces the level of opioid release when several tablets are swallowed. Aversion irritates the nasal passages upon snorting the product. Its product portfolio includes Oxaydo, an opioid analgesic; Nexafed and Nexafed Sinus Pressure plus that contain pseudoephedrine. The company markets its products in the US and Canada. Acura is headquartered in Palatine, Illinois, the US.

Acura Pharmaceuticals Inc (ACUR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Acura Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Licensing Agreements 12
MainPointe Pharma Enters into Licensing Agreement with Acura Pharma 12
KemPharm Enters into Licensing Agreement with Acura Pharma 14
Egalet Enters into Licensing Agreement with Acura Pharma 15
Equity Offering 16
Acura Pharma Raises USD4 Million in Private Placement of Units 16
Acura Pharmaceuticals Files Registration Statement for Public Offering of Shares 17
Acura Pharma Raises USD7.6 Million in Private Placement of Shares 18
Acura Pharma Completes Second Tranche Of Public Offering Of Shares For US$3.4 Million 20
Acquisition 21
Acura Pharma Plans to Sell Itself 21
Acura Pharmaceuticals Inc – Key Competitors 22
Acura Pharmaceuticals Inc – Key Employees 23
Acura Pharmaceuticals Inc – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Aug 14, 2018: Acura Pharmaceuticals announces second quarter 2018 financial results 25
Jun 29, 2018: Acura Pharmaceuticals Reports First Quarter 2018 Financial Results 26
Jun 07, 2018: Acura Pharmaceuticals Announces Fourth Quarter 2017 and Full Year 2017 Financial Results 27
Nov 13, 2017: Acura Pharmaceuticals Announces Third Quarter 2017 Financial Results 28
Aug 14, 2017: Acura Pharmaceuticals Announces Second Quarter 2017 Financial Results 29
May 12, 2017: Acura Pharmaceuticals Announces First Quarter 2017 Financial Results 30
Mar 31, 2017: Acura Pharmaceuticals Announces Fourth Quarter 2016 and Full Year 2016 Financial Results 31
Product News 32
09/11/2017: Acura Pharmaceuticals Presenting New LIMITx Clinical Data at the 19th Annual Rodman & Renshaw Conference 32
06/28/2017: Acura Pharmaceuticals Advances LTX-04 and its LIMITx Technology 33
Clinical Trials 34
May 18, 2017: Acura Pharmaceutical Initiates Second Clinical Study on LTX-04 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Acura Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Acura Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
MainPointe Pharma Enters into Licensing Agreement with Acura Pharma 12
KemPharm Enters into Licensing Agreement with Acura Pharma 14
Egalet Enters into Licensing Agreement with Acura Pharma 15
Acura Pharma Raises USD4 Million in Private Placement of Units 16
Acura Pharmaceuticals Files Registration Statement for Public Offering of Shares 17
Acura Pharma Raises USD7.6 Million in Private Placement of Shares 18
Acura Pharma Completes Second Tranche Of Public Offering Of Shares For US$3.4 Million 20
Acura Pharma Plans to Sell Itself 21
Acura Pharmaceuticals Inc, Key Competitors 22
Acura Pharmaceuticals Inc, Key Employees 23
Acura Pharmaceuticals Inc, Subsidiaries 24

List of Figures
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Acura Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Acura Pharmaceuticals Inc (ACUR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • BDI – BioEnergy International AG:企業の戦略的SWOT分析
    BDI - BioEnergy International AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Russian Reinsurance Company
    Russian Reinsurance Company - Strategy, SWOT and Corporate Finance Report Summary Russian Reinsurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • M1 Ltd:企業の戦略的SWOT分析
    M1 Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Electronic Arts Inc. (EA):企業の財務・戦略的SWOT分析
    Electronic Arts Inc. (EA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Keio Corporation (9008):企業の財務・戦略的SWOT分析
    Keio Corporation (9008) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Meiji Holdings Co, Ltd.
    Meiji Holdings Co, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Meiji Holdings Co, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Arista Investors Corp:企業の戦略・SWOT・財務情報
    Arista Investors Corp - Strategy, SWOT and Corporate Finance Report Summary Arista Investors Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Fairfax Media Limited:企業の戦略・SWOT・財務分析
    Fairfax Media Limited - Strategy, SWOT and Corporate Finance Report Summary Fairfax Media Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Kathmandu Holdings Limited:企業の戦略・SWOT・財務分析
    Kathmandu Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Kathmandu Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Solvay SA (SOLB):電力:M&Aディール及び事業提携情報
    Summary Solvay SA (Solvay) is a chemical manufacturing company, which carries out production of specialty polymers, essential chemicals, silica and rare earth systems, consumer chemicals, polyamide and intermediates. In addition, the company manufactures additives, engineering plastics, diphenols an …
  • Intra-Cellular Therapies Inc (ITCI):企業の財務・戦略的SWOT分析
    Summary Intra-Cellular Therapies Inc (ITI) is a novel drug manufacturer. The company offers product platform such as ITCI Pipeline that includes lumateperone, ITI-007 platform, PDE inhibitor platform and drug discovery platform. The company’s lead product candidate ITI-007-lumateperone is to treat s …
  • Sohar Power Company SAOG:発電所・企業SWOT分析
    Sohar Power Company SAOG - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key empl …
  • M. Dias Branco SA Ind Com de Alimentos:企業の戦略・SWOT・財務情報
    M. Dias Branco SA Ind Com de Alimentos - Strategy, SWOT and Corporate Finance Report Summary M. Dias Branco SA Ind Com de Alimentos - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Iovance Biotherapeutics Inc (IOVA):企業の財務・戦略的SWOT分析
    Iovance Biotherapeutics Inc (IOVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Veristat LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Veristat LLC (Veristat), a subsidiary of Veristat Holding Inc is a clinical research organization that conducts clinical trials. The organization offers services such as clinical project management, data management, clinical monitoring, biostatistics, medical writing, project management, reg …
  • Security Networks AG:企業の戦略・SWOT・財務情報
    Security Networks AG - Strategy, SWOT and Corporate Finance Report Summary Security Networks AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Clearside BioMedical Inc (CLSD):企業の財務・戦略的SWOT分析
    Summary Clearside BioMedical Inc (Clearside) is a clinical biopharmaceutical company that develops treatments for vision impairment associated with uveitic macular edema. The company’s pipeline products comprise Uveitis, macular edema associated with non- infectious uveitis; RVO - Retinal Vein Occlu …
  • Independent Electricity System Operator:企業の戦略的SWOT分析
    Independent Electricity System Operator - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • The American Energy Group Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary The American Energy Group Ltd (American Energy Group), formerly Belize-American Corp, is an oil and natural gas company that develops, explores, acquire, and produces oil and natural gas producing assets. The company owns interest in two oil and gas leases in Southeast Texas American Energy …
  • Genetic Analysis AS:製薬・医療:M&Aディール及び事業提携情報
    Summary Genetic Analysis AS (Genetic Analysis) is a molecular diagnostic company that mapping of microbiota by utilizing the GA-map technology to develop IVD tests in various diseases. The company develops gene-based routine tests for the mapping and diagnosis of diseases related to dysbiosis and ba …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆